Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Uterine Cervical Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Thyroid Cancer, Papillary 3Lung Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Adenocarcinoma, Follicular 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Salivary Gland Neoplasms 2Rectal Neoplasms 2Prostatic Neoplasms 2Mouth Neoplasms 2Liver Neoplasms 2Laryngeal Neoplasms 2Kidney Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Colorectal Neoplasms 2von Hippel-Lindau Disease 1Vaginal Neoplasms 1Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Tongue Neoplasms 1Thyroid Carcinoma, Anaplastic 1

Interventions

Temozolomide 4Bevacizumab 3Vorinostat 2Immunoglobulin G 2Disulfides 2veliparib 1romidepsin 1ispinesib 1cediranib 1Vincristine 1Prednisone 1Nivolumab 1Methotrexate 1Lomustine 1Lapatinib 1Irinotecan 1Ifosfamide 1Gelclair 1Fluorodeoxyglucose F18 1Etoposide 1Dexamethasone 1Clinical Laboratory Techniques 1Cisplatin 1Carboplatin 1Calcium Dobesilate 1CK0238273 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Spinal Cord Neoplasms × Fluorodeoxyglucose F18 × Clear all
NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

National Cancer Institute (NCI)

Phase 2 Completed
97 enrolled 35 charts
CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡